Imaging software developer Mirada Medical has signed a three-year master service agreement with international healthcare firm BTG for multiple projects to support BTG's portfolio of interventional medicine products.
Mirada and BTG have been collaborating since October 2015 to develop software to optimize radioembolization therapy with radioisotope firm Nordion's TheraSphere yttrium-90 glass microsphere treatment for liver cancer.
That collaboration resulted in Simplicit90Y, customized dosimetry software designed to help physicians personalize treatment with Y-90 therapies, such as TheraSphere.
The Simplicit90Y software received CE Mark certification in Europe in October 2016.
